Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Inclusion Criteria: * Male or female ≥ 9 years of age. * Primary, axillary hyperhidrosis of at least 6 months duration. * Hyperhidrosis Disease Severity Scale (HDSS) of 3 or 4 at Baseline. * Axillary Sweating Daily Diary (ASDD) ≥ 4 at Baseline. * Sweat production of at least 50 mg over 5 minutes in each axilla assessed gravimetrically. Exclusion Criteria: * Prior surgical procedure for hyperhidrosis. * Prior axillary treatment with an anti-hyperhidrosis medical device (approved or investigational). * Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1. * Previous active treatment in the Dermira DRM04-HH01 or DRM04-HH02 clinical trials. * Axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks of Baseline. * Subjects on new or regimens of psychotherapeutic medications that have changed within 2 months of baseline. * Treatment with systemic anticholinergics within 4 weeks of the baseline visit unless dosing has been stable for at least 4 months. * Other treatment with glycopyrrolate within 4 weeks prior to Baseline. * Secondary axillary hyperhidrosis or presence of a condition that may cause secondary hyperhidrosis. * History of Sjögren's syndrome or Sicca syndrome. * History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness. * Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy. * History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter. * Other systemic diseases or active uncontrolled infections, or any other condition which, in the judgment of the Investigator, would put the subject at unacceptable risk for participation in the study.